Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.66 USD | +4.45% | +3.54% | 0.00% |
Valuation
Fiscal Period: December | 2024 | 2025 | 2026 |
---|---|---|---|
Capitalization 1 | 410.3 | - | - |
Enterprise Value (EV) 1 | 206.6 | 350.5 | 340.8 |
P/E ratio | - | - | - |
Yield | - | - | - |
Capitalization / Revenue | - | 27.4 x | - |
EV / Revenue | - | 23.4 x | - |
EV / EBITDA | -4.77 x | -7.52 x | -4.75 x |
EV / FCF | -5.58 x | -8.35 x | -5.01 x |
FCF Yield | -17.9% | -12% | -20% |
Price to Book | - | -9.05 x | 7.21 x |
Nbr of stocks (in thousands) | 25,723 | - | - |
Reference price 2 | 16.66 | 16.66 | 16.66 |
Announcement Date | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|
Net sales 1 | - | - | 15 | - |
EBITDA 1 | - | -43.33 | -46.6 | -71.78 |
EBIT 1 | - | -45.95 | -40.9 | -80.07 |
Operating Margin | - | - | -272.64% | - |
Earnings before Tax (EBT) | 23.17 | - | - | - |
Net income | 22.72 | - | - | - |
Net margin | - | - | - | - |
EPS | - | - | - | - |
Free Cash Flow 1 | - | -37 | -42 | -68 |
FCF margin | - | - | -280% | - |
FCF Conversion (EBITDA) | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - |
Dividend per Share | - | - | - | - |
Announcement Date | 2/15/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
---|---|---|---|---|
Net sales 1 | - | - | - | - |
EBITDA | - | - | - | - |
EBIT 1 | -9.93 | -9.5 | -12.6 | -15.7 |
Operating Margin | - | - | - | - |
Earnings before Tax (EBT) | - | - | - | - |
Net income | - | - | - | - |
Net margin | - | - | - | - |
EPS | - | - | - | - |
Dividend per Share | - | - | - | - |
Announcement Date | 5/16/24 | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|
Net Debt 1 | - | - | - | - |
Net Cash position 1 | - | 204 | 59.7 | 69.5 |
Leverage (Debt/EBITDA) | - | - | - | - |
Free Cash Flow 1 | - | -37 | -42 | -68 |
ROE (net income / shareholders' equity) | - | - | - | -663% |
ROA (Net income/ Total Assets) | - | - | - | - |
Assets | - | - | - | - |
Book Value Per Share 2 | - | - | -1.840 | 2.310 |
Cash Flow per Share | - | - | - | - |
Capex 1 | - | 0.43 | 0.35 | 0.55 |
Capex / Sales | - | - | 2.34% | - |
Announcement Date | 2/15/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
0.00% | 410M | |
+48.54% | 56.87B | |
+37.15% | 39.72B | |
-6.02% | 39.27B | |
-6.90% | 28.73B | |
+12.97% | 26.21B | |
-16.91% | 19.79B | |
+31.71% | 12.28B | |
+28.18% | 12.23B | |
+0.38% | 12.12B |
- Stock Market
- Equities
- CTNM Stock
- Financials Contineum Therapeutics, Inc.